News
PDSB
0.2200
0.00%
0.0000
PDS Biotechnology Amends Promissory Note, Tightens Financing Terms
TipRanks · 3d ago
PDS Biotechnology’s Phase 3 Head and Neck Cancer Trial Termination: What It Means for Investors
TipRanks · 5d ago
Weekly Report: what happened at PDSB last week (0824-0828)?
Weekly Report · 08/31 09:06
PDS Biotechnology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 08/26 11:38
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target
Benzinga · 08/26 11:28
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 08/26 10:20
PDS Biotechnology Restructures Workforce and Leadership Team
TipRanks · 08/25 20:29
PDS Biotechnology Intends To Cut Workforce By 36%; Removes Stephan Toutain As COO, Effective Aug. 21
Benzinga · 08/25 20:11
Weekly Report: what happened at PDSB last week (0817-0821)?
Weekly Report · 08/24 09:06
PDS Biotechnology Says Lars Boesgaard To Resign As CFO, Principal Financial Officer & Principal Accounting Officer Effective Sept 12; Frank Bedu-Addo Appointed As Interim Principal Financial Officer
Benzinga · 08/19 21:00
Weekly Report: what happened at PDSB last week (0810-0814)?
Weekly Report · 08/17 09:06
PDS Biotechnology Shareholders Approve Expanded Authorized Stock
TipRanks · 08/14 12:28
PDS Biotechnology Price Target Cut to $7.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 08/13 16:24
PDS Biotechnology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/13 16:24
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7
Benzinga · 08/13 16:17
PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate
Benzinga · 08/13 13:06
PDS Biotechnology GAAP EPS of -$0.18 misses by $0.05
Seeking Alpha · 08/13 12:35
*PDS Biotechnology 2Q Loss $9.75M >PDSB
Dow Jones · 08/13 12:32
Press Release: PDS Biotech Reports Second Quarter 2026 Financial Results
Dow Jones · 08/13 12:30
*PDS Biotechnology 2Q Loss/Shr 18c >PDSB
Dow Jones · 08/13 12:30
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.